Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (5218)	12/31/1997 4:47:00 PM
From: Mike Kapul	Read Replies (1) \| Respond to of 17367

Thanks Cacaito. >>Mike K, the worst case is not a strikingly good case, but bearable: >> >> N1 65----20% >> N2 65---- 8% p value 0.0508 just statistically significant. Hopefully, the results will be better than that by next DSMB. But if there is no early approval, these calculations put things in perspective - no reason to pull hair out and sell it all, not yet at least. A 2.5 times improvement in suvival and a 50/50 case at 130 patients would be a shoe-in for approval at 200. (Just realized that my last sentence sounds almost like "Mr. XX, if you have the winning number, you the guaranteed winner of $10 Mil .. :) Thanks again to everyone on this board. Happy new year and good luck. Mike